Abstract: Described herein is a wet wipe including a substrate and a lotion. The substrate includes from about 55% to about 85% polyester. The lotion includes (a) from about 98.5% to about 99.5% water; (b) from about 0.055% to about 0.1% of an organic acid; and (c) a pH buffering system. The lotion has a pH from about 3.6 to about 4.8.

Abstract: Provided are hypromellose acetate succinates (HPMCAS) for use as a hot-melt extrusion carrier having a volume average particle size (D50) of from 70 to 300 as measured by dry laser diffraction and a loose bulk density of from 0.25 to 0.40 g/cm3; and a hot-melt extrusion composition comprising the HPMCAS and a drug. Also provided is a method for producing a hot-melt extrudate including the steps of: hot-melting the hot-melt extrusion composition at a hot-melt temperature equal to or higher than a melting temperature of the HPMCAS, or at a hot-melt temperature equal to or higher than a temperature at which both of the HPMCAS and the drug become melt; and extruding the hot-melted composition.

Abstract: A method of promoting hemostasis in the mouth or oral cavity utilizes a non-absorbent, low surface energy and highly conformable non-disruptive hemostasis material. Traditional wound packing material is highly absorbent and has large open surfaces that allow clot forming materials, such as the platelet plug to adhere to the packing material and whereupon removal, the clot is disrupted. A non-disruptive highly conformable hemostasis material does not have large open pores and therefore does not adhere to forming clots. A non-disruptive hemostasis material may consist of expanded polytetrafluoroethylene that has a pore size of no more than about 10 microns. A non-disruptive hemostasis material may comprise a thin film of material over a portion of the outside surface that is non-absorbent and thin to allow for conforming into an oral cavity, such as from a tooth extraction. A thin film may cover porous material, such as a foam, that may be elastomeric.

Abstract: Provided are a drug-containing particle capable of suppressing dissolution of a drug in the oral cavity to suppress an unpleasant taste thereof and having excellent dissolution of the drug in the digestive tract after passing through the oral cavity; a method for preparing the drug-containing particle; a coating composition used for preparing the drug-containing particle; and a solid preparation having the drug-containing particle. More specifically, provided are a coating composition having 100 parts by weight of a cellulose-based enteric base and 50 parts by weight or less of a water-soluble cellulose ether; a drug-containing particle having a drug-containing core and a coat portion obtained by coating the core with the coating composition; a solid preparation having the drug-containing particle; and a method for preparing a drug-containing particle having a step of coating the drug-containing core with the coating composition.

Abstract: Described herein is a wet wipe including a substrate and a lotion. The substrate includes from about 14.5% to about 100% cotton. The lotion includes from about 98% to about 99.5% water and has an Equivalence Value from about 30 to about 95.

Abstract: Described herein is an array of wet wipe packages including a first package and a second package. The first package includes a first wet wipe having a first nonwoven material and a first lotion. The first nonwoven material includes from about 14.5% to about 45% cotton. The first lotion includes from about 98.5% to about 99.5% water and is devoid of fragrance and/or perfume. The first wet wipe has an Equivalence Value from about 30 to about 95. The second package includes a second wet wipe having a second nonwoven material and a second lotion. The second lotion is different than the first lotion. The first package and the second package are designed to be sold individually. The first package and the second package each include a common brand name.

Abstract: The present patent application relates a process for the production of compressed tablets using specific coated particles, wherein the coating (system) comprises at least one wax and/or at least one fat. Furthermore it relates to compressed (compacted) tablets and as well as to specific coated particles.

Abstract: The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.

Abstract: There is provided a method for treating pigmented lesions comprising a composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant. The composition may further comprise at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.

Abstract: The inventive subject matter relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children.

Abstract: Disclosed a pregabalin-containing, high swellable, oral sustained-release triple layer tablet suitable for administration once daily.

Abstract: The present invention provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, b. in an aqueous vehicle. wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives. Also, the present invention provides a method of treatment of inflammatory disorder of the eye, said method comprising administering into the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02% to 0.04% weight by volume in an aqueous vehicle, wherein the solution is free of oil and wherein the solution is administered twice-a-day.

Abstract: A treatment solution has an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A wipe has a substrate, a treatment solution impregnated into the substrate, the treatment solution including an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 6 wt % or below of the total solution. A treatment solution, has an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 6 wt % or below of the total solution.

Abstract: Disclosed is an oil-in-water type organopolysiloxane emulsion that is stable and has smaller particle diameters for a long period of time even in cases where a low-polarity organopolysiloxane and a cationic surfactant are used. The emulsion comprises: (A) 100 parts by weight of a diorganopolysiloxane having a viscosity of 2 to 100,000 mPa·s at 25° C., (B) 0.5 to 30 parts by weight of a cationic surfactant, (C) 0.1 to 10 parts by weight of a nonionic surfactant, and (D) 11 to 550 parts by weight of water, wherein a content of component (C) is equal to or less than a content of component (B), and wherein an average particle diameter of component (A) in the emulsion is 600 nm or less. Related methods and cosmetics are also disclosed.

Abstract: Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon.

Abstract: The present technology provides personal care compositions that include about 0.1 wt % to about 10 wt % of (Formula), or a mixture of any two or more thereof; wherein n is 0, 1, or 2; m is 1, 2, or 3; p is 0, 1, or 2; and q is 1, 2, or 3; about 0.1 wt % to about 30 wt % of a UV-B sunscreen oil; about 0.1 wt % to about 30 wt % of a nonionic surfactant of Formula I (I) where R1 is a C6-C12 alkyl group; r is an integer from 6 to 13, and the nonionic surfactant has a hydrophilic-lipophilic balance of about 10 to about 14; and about 40 wt % to about 96 wt % of the personal care composition is water.

Abstract: The present disclosure is directed to fatty-acid glycerol ester derivative compounds containing a targeting bisphosphonate group. The disclosure further include pharmaceutical or biomedical compositions comprising these compounds, and methods of using these compounds and compositions forming microbubbles. The microbubbles have affinity for metal-containing, especially calcium-containing, bodies and/or biological targets. In certain embodiments, these compositions are useful for providing targeted placement of microbubbles capable of cavitation on application of high frequency energy.

Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Abstract: Provided is a polyether-based urethane foam for impregnating a cosmetic composition. The polyether-based urethane foam has excellent touch feel, portability and stability.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).